Table 1.

Patient characteristics

	N (%)
Gender
Male	48 (60.8)
Female	31 (39.2)
Age
Median (range)	51 (0–73)
Underlying disease
Acute myeloblastic leukemia	30 (38)
Acute lymphoblastic leukemia	12 (15.2)
Myelodysplastic syndrome	11 (13.9)
Multiple myeloma	3 (3.8)
Hodgkin disease	2 (2.5)
Non-Hodgkin disease	13 (16.5)
Myelofibrosis	4 (5.1)
Others	4 (5.1)
Disease status previous HSCT
CR	47 (59.5)
PR	13 (16.5)
SD	11 (13.9)
Others	8 (10,1)
Type of transplant
Related HLA identical donor	33 (41.7)
Haploidentical	7 (8.8)
Unrelated donor	39 (49.3)
Conditioning regimen
Myeloablative	34 (43)
Reduced-intensity	45 (57)
Source
Peripheral blood	75 (95)
Bone marrow	2 (2.5)
Umbilical cord	2 (2.5)

Acute GVHD (n = 23)	N (%)
Grades
2–4	23 (100)
3–4	20 (87)
Organs involved
Skin	16 (69.6)
Gut	21 (95.5)
Liver	13 (59.1)
Previous lines of therapy
1	4 (18.2)
2	7 (31.8)
3	6 (26.1)
>3	6 (27.2)

Chronic GVHD (n = 56)	N (%)
NIH score
Mild	0 (0)
Moderate	28 (50)
Severe	28 (50)
Organs involved
Skin	44 (78.5)
Sclerotic changes	25 (41.1)
Resembling lichen planus	2 (3.6)
Rash	13 (23.2)
Hyper/hypopigmentation	3 (5.4)
Ichthyosis	3 (5.4)
Oral	33 (58.9)
Ocular	23 (41)
Gut	16 (28.6)
Liver	10 (17.8)
Lung	26 (45)
Joint mobility disfunction	22 (39.4)
Urinary tract	7 (12.5)
Esophageal membrane	2 (3.6)
Pericardial/pleural effusion	2 (3.6)
Nephrotic syndrome	1 (1.8)
Neuropathy	1 (1.8)
Microangiopathy	1 (1.8)
Polymyositis	3 (5.3)
Previous lines of therapy
1	4 (7.1)
2	20 (35.7)
3	11 (19.6)
>3	21 (37.6)